Michael D. Kalos
253 works · 26,502 citations · h-index 54
Top works
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- “MIATA”—Minimal Information about T Cell Assays
- Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34 + Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade